Clinical Trials
18 trialsNCT03301350 2026-02-13
Neoadjuvant Carbo/Paclitaxel Followed by Doxorubicin/Cyclophosphamide in Breast Cancer
University of Wisconsin, Madison
Phase 2 Completed
NCT03036488 2025-10-29
MK-3475-522
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT00861705 2025-09-30
Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed by Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT06965361 2025-05-16
TIL; PD1; PDL1
Ziauddin University
Completed
NCT01818063 2025-04-30
Carboplatin and Combination Chemotherapy With or Without Veliparib in Treating Patients With Stage IIB-IIIC Breast Cancer
Thomas Jefferson University
Phase 2 Completed
NCT02938442 2024-11-07
Vaccination of Triple Negative Breast Cancer Patients
University of Arkansas
Phase 1/2 Completed
NCT02648477 2024-03-19
Pembrolizumab and Doxorubicin Hydrochloride or Anti-Estrogen Therapy in Treating Patients With Triple-Negative or Hormone Receptor-Positive Metastatic Breast Cancer
City of Hope Medical Center
Phase 2 Completed
NCT05112536 2024-03-12
Trilaciclib, a CDK4/6 Inhibitor, in Patients With Early-Stage Triple Negative Breast Cancer
G1 Therapeutics, Inc.
Phase 2 Completed
NCT02456857 2024-02-13
Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
M.D. Anderson Cancer Center
Phase 2 Completed
NCT03197935 2023-10-26
IMpassion031
Hoffmann-La Roche
Phase 3 Completed
NCT04081389 2023-09-11
Chemokine Modulation Therapy and Standard Chemotherapy Before Surgery for the Treatment of Early Stage Triple Negative Breast Cancer
Roswell Park Cancer Institute
Phase 1 Completed
NCT04584112 2023-03-15
A Study of the Safety, Efficacy, and Pharmacokinetics of Tiragolumab in Combination With Atezolizumab and Chemotherapy in Participants With Triple-Negative Breast Cancer
Hoffmann-La Roche
Phase 1 Completed
NCT02413320 2021-05-10
NeoSTOP
University of Kansas Medical Center
Phase 2 Completed
NCT02032277 2021-01-20
A Study Evaluating Safety and Efficacy of the Addition of ABT-888 Plus Carboplatin Versus the Addition of Carboplatin to Standard Chemotherapy Versus Standard Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer
AbbVie
Phase 3 Completed
NCT02622074 2020-09-10
KEYNOTE 173
Merck Sharp & Dohme LLC
Phase 1 Completed
NCT01145430 2017-12-22
Veliparib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Completed
NCT01672671 2015-11-03
BRCA1-associated DNA Repair Dysfunction in Patients With Early Triple Negative Breast Cancer Treated With Neoadjuvant Platinum-based Chemotherapy
Russian Academy of Medical Sciences
Phase 2 Completed
NCT01969032 2014-11-05
Induction Preoperative Chemotherapy for Patients With Locally Advanced Triple Negative Breast Cancer
Russian Academy of Medical Sciences
Phase 2 Completed